{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:13Z","timestamp":1786116553212,"version":"build-2736575974"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint blockade has transformed cancer treatment, but its clinical success depends on releasing antitumor immunity without collapsing peripheral tolerance. Biomarkers such as PD-L1 expression, mismatch-repair deficiency and tumor mutational burden capture only selected aspects of this balance and provide limited guidance on immune-related adverse events (irAEs). This Review examines inhibitory receptor states as dynamic readouts of the therapeutic window in cancer immunotherapy. Rather than treating PD-1, CTLA-4, LAG-3, TIM-3, TIGIT, VISTA and NKG2A as isolated abundance markers, we discuss how their signaling intersects with CD3, CD28 and cytokine-driven activation, immune-cell differentiation, tissue localization and homeostatic restraint. We further consider how checkpoint blockade converts these circuits into either tumor control or organ-specific immune injury. Evidence from tissue pathology, blood immunomonitoring, single-cell and spatial multi-omics, routine laboratory markers, imaging and emerging host-immune surrogates is integrated into a longitudinal, regimen-specific framework. We argue that clinically useful models should jointly estimate response and toxicity risk, distinguishing reinvigoratable antitumor states from fixed dysfunction and autoreactive vulnerability. Such an approach could support patient selection, regimen tailoring, early toxicity surveillance and more precise use of combination immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1762484","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:05:06Z","timestamp":1786014306000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibitory receptor states, immune homeostasis and the benefit\u2013risk boundary of cancer checkpoint blockade"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaodong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Cancer Center and Institution of Stress Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gao","sequence":"additional","affiliation":[{"name":"The Center of Nuclear Stress Medicine, The Second Affiliated Hospital (Nuclear Industry 416 Hospital), Chengdu Medical College","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjiang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Center and Institution of Stress Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songli","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchen","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouping","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Center and Institution of Stress Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2085","article-title":"Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-x","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","article-title":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer","volume":"40","author":"Salom\u00e9","year":"2022","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.21417\/sw2019ci","article-title":"Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states","volume":"50","author":"Wei","year":"2019","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1\u2013targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg0539","article-title":"PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors","volume":"8","author":"Gill","year":"2023","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annonc.2021.10.090","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101640","article-title":"Pan-cancer mapping of single CD8(+) T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","volume":"5","author":"Tooley","year":"2024","journal-title":"Cell Rep Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008875","article-title":"Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing","volume":"13","author":"Taube","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007180","article-title":"Single-cell sequencing on CD8(+) TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer\/testis antigen in non-small cell lung cancer","volume":"11","author":"Komuro","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00262-025-04086-0","article-title":"High baseline PD-1+ CD8 T cells and TIGIT+ CD8 T cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancer","volume":"74","author":"Dutta","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw0902","article-title":"CTLA-4\u2013mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells","volume":"4","author":"Ovcinnikovs","year":"2019","journal-title":"Sci Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0404","article-title":"Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade","volume":"28","author":"Johannet","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac161","article-title":"Endocrine autoantibodies determine immune checkpoint inhibitor-induced endocrinopathy: a prospective study","volume":"107","author":"Labadzhyan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2323052121","article-title":"Injury-induced myosin-specific tissue-resident memory T cells drive immune checkpoint inhibitor myocarditis","volume":"121","author":"Kalinoski","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.067189","article-title":"T cells and macrophages drive pathogenesis of immune checkpoint inhibitor myocarditis","volume":"149","author":"\u010cih\u00e1kov\u00e1","year":"2024","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.198203","article-title":"Pretreatment naive T cells are associated with severe irAE following PD-1\/CTLA-4 checkpoint blockade for melanoma","volume":"11","author":"Marks","year":"2026","journal-title":"JCI Insight"},{"key":"B50","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-10-0097","article-title":"Analytic variability in immunohistochemistry biomarker studies","volume":"19","author":"Anagnostou","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.21417\/ty2021icb","article-title":"T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors","volume":"12","author":"Yamauchi","year":"2021","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1038\/s41467-022-29342-0","article-title":"Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma","volume":"13","author":"Holm","year":"2022","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03541-0","article-title":"Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition","volume":"72","author":"van Eijs","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B57","doi-asserted-by":"publisher","first-page":"17450","DOI":"10.1038\/s41598-025-02597-5","article-title":"The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.immuni.2021.08.019","article-title":"Resident memory CD8(+) T cells in regional lymph nodes mediate immunity to metastatic melanoma","volume":"54","author":"Molodtsov","year":"2021","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba7918","article-title":"TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells","volume":"5","author":"Sekine","year":"2020","journal-title":"Sci Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-022-35238-w","article-title":"A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer","volume":"14","author":"Tietscher","year":"2023","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"8511","DOI":"10.1038\/s41598-021-88156-0","article-title":"Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue","volume":"11","author":"Parra","year":"2021","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007023","article-title":"Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer","volume":"11","author":"Marcos Rubio","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100197","article-title":"Multiplex immunohistochemistry and immunofluorescence: a practical update for pathologists","volume":"36","author":"Harms","year":"2023","journal-title":"Mod Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/srep20686","article-title":"Standardizing flow cytometry immunophenotyping analysis from the human immunophenotyping consortium","volume":"6","author":"Finak","year":"2016","journal-title":"Sci Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00415","article-title":"Validation of CyTOF against flow cytometry for immunological studies and monitoring of human cancer clinical trials","volume":"9","author":"Gadalla","year":"2019","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010455","article-title":"Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer","volume":"13","author":"Kim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00262-025-04061-9","article-title":"Immunotyping of thyroid cancer for clinical outcomes and implications","volume":"74","author":"Xu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100139","article-title":"Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Cell Rep Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101435","article-title":"Multimodal fusion artificial intelligence model to predict risk for MACE and myocarditis in cancer patients receiving immune checkpoint inhibitor therapy","volume":"4","author":"Ayoub","year":"2025","journal-title":"JACC Adv"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1038\/s41467-025-58512-z","article-title":"Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors","volume":"16","author":"Kao","year":"2025","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41586-026-10243-x","article-title":"Thymic health and immunotherapy outcomes in patients with cancer","volume":"652","author":"Bernatz","year":"2026","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41379-021-00919-2","article-title":"Digital pathology and artificial intelligence in translational medicine and clinical practice","volume":"35","author":"Baxi","year":"2022","journal-title":"Mod Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-2156","article-title":"Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value","volume":"24","author":"Mazzaschi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00582-9","article-title":"HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study","volume":"23","author":"Naranbhai","year":"2022","journal-title":"Lancet Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.46400","article-title":"Analysis of human leukocyte antigen DR alleles, immune-related adverse events, and survival associated with immune checkpoint inhibitor use among patients with advanced Malignant melanoma","volume":"5","author":"Akturk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008056","article-title":"Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4(+) na\u00efve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma","volume":"12","author":"Kovacsovics-Bankowski","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061308","article-title":"Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane","year":"2021","journal-title":"Sci Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.120.018306","article-title":"Decreased absolute lymphocyte count and increased neutrophil\/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Drobni","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15246","article-title":"Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: a single-center retrospective study in Japan","volume":"47","author":"Otsuka","year":"2020","journal-title":"J Dermatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","article-title":"Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer","volume":"42","author":"Dyikanov","year":"2024","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.06.009","article-title":"Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy","volume":"7","author":"Cheng","year":"2025","journal-title":"JACC: Cardio Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf147","article-title":"The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors","volume":"30","author":"Gvili Perelman","year":"2025","journal-title":"Oncologist"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2021.100293","article-title":"Interpretable systems biomarkers predict response to immune-checkpoint inhibitors","volume":"2","author":"Lapuente-Santana","year":"2021","journal-title":"Patterns (N Y)"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1732079","article-title":"Artificial intelligence-enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation","volume":"17","author":"Wang","year":"2026","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1762484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:05:07Z","timestamp":1786014307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1762484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2026.1762484"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1762484","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1762484"}}